Extends Medicare drug price negotiation delays for certain biological products to encourage cheaper biosimilar drugs.
This bill would change Medicare rules to allow drug companies to delay price negotiations for certain biological products for up to two years, instead of one. This delay would happen automatically if a cheaper, similar drug (a biosimilar) is expected to enter the market soon. If the biosimilar doesn't launch as planned, the original drug maker would pay a rebate.
Today, Medicare price negotiations for certain biological products can be delayed for one year if a biosimilar is likely to enter the market. This bill would extend that potential delay to two years and create an automatic delay process. If a biosimilar doesn't launch as expected after the delay, the original drug manufacturer would pay a rebate. This rebate would be 75 percent for Part D drugs or 80 percent for Part B drugs.
S 5571 · 119th Congress · AI Summary by gemini-2.5-flash · 10/10
Sign in to see your representatives' phone numbers
1 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.